Business Overview Relmada Therapeutics, Inc. (Relmada, the Company, we or us) (a Nevada corporation), is a publicly traded, clinical-stage biotechnology company. We substantially redesigned our development programs following a comprehensive strategic review in late 2024 and early 2025. We concluded in our review that the most promising path to create shareholder value was to lever our extensive drug development expertise and clinical operations capabilities by acquiring new development candidate...
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001213900-26-031862 | EDGAR | 49K words |
| 2025-03-27 | 2024-12-31 | 0001013762-25-003426 | EDGAR | — |
| 2024-03-19 | 2023-12-31 | 0001213900-24-024013 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0001213900-23-022463 | EDGAR | — |
| 2022-03-25 | 2021-12-31 | 0001213900-22-015012 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001213900-21-017556 | EDGAR | — |
| 2019-09-24 | 2019-06-30 | 0001213900-19-018787 | EDGAR | — |
| 2018-09-28 | 2018-06-30 | 0001213900-18-013238 | EDGAR | — |
| 2017-09-28 | 2017-06-30 | 0001213900-17-010097 | EDGAR | — |
| 2016-09-09 | 2016-06-30 | 0001213900-16-016664 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001213900-25-109983 | EDGAR | 17K words |
| 2025-08-07 | 2025-06-30 | 0001213900-25-073073 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001213900-25-042025 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001213900-24-095398 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001213900-24-066111 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001213900-24-040856 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001213900-23-084737 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001213900-23-064519 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001213900-23-038533 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001213900-22-071154 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001213900-22-046934 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001213900-22-024229 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-20 | 0001213900-26-032403 | EDGAR | 4K words |
| 2026-03-09 | 0001213900-26-024918 | EDGAR | — |
| 2025-12-15 | 0001213900-25-121461 | EDGAR | — |
| 2025-11-13 | 0001213900-25-110088 | EDGAR | — |
| 2025-11-05 | 0001213900-25-106398 | EDGAR | — |
| 2025-11-04 | 0001213900-25-105593 | EDGAR | — |
| 2025-09-17 | 0001213900-25-088360 | EDGAR | — |
| 2025-09-16 | 0001213900-25-087926 | EDGAR | — |
| 2025-09-10 | 0001213900-25-086389 | EDGAR | — |
| 2025-09-02 | 0001213900-25-082910 | EDGAR | — |
236 total filings indexed. 204 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001553643 |
| Ticker | RLMD |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.relmada.com |
| Listed | 2014-03-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report